Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CLXH254C12201
Novartis Pharmaceuticals
Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
1 trial -
CMAS825D12201
Novartis Pharmaceuticals
Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.
1 trial -
CMBG453B12206B
Novartis Pharmaceuticals
intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
1 trial -
CPHE885B12201
Novartis Pharmaceuticals
Adult patients with relapsed and refractory multiple myeloma
1 trial -
CPK850
Novartis Pharmaceuticals
Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
1 trial -
CPKC412A2218
Novartis Pharmaceuticals
untreated FLT3-mutated Acute Myeloid Leukemia
1 trial -
CPKN605A12201
Novartis Pharmaceuticals
Atrial Fibrillation
1 trial -
CQUC398A12201
Novartis Pharmaceuticals
Knee osteoarthritis
1 trial -
CQVM149C2201
Novartis Pharmaceuticals
Asthma
1 trial -
CSJ117
Novartis Pharmaceuticals
Asthma
2 trials -
CTIN816A12201
Novartis Pharmaceuticals
Acute kidney injury
1 trial -
CTIN816B12202
Novartis Pharmaceuticals
Sepsis associated acute kidney injury
1 trial -
CTQJ230A12203
Novartis Pharmaceuticals
Calcific Aortic Valve Stenosis
1 trial -
CVAY736A2103
Novartis Pharmaceuticals
Sjögren's syndrome
1 trial -
CVAY736A2202
Novartis Pharmaceuticals
Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus
1 trial -
CVAY736Q12202B
Novartis Pharmaceuticals
Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)
1 trial -
CVAY736S12201
Novartis Pharmaceuticals
Diffuse cutaneous systemic sclerosis (dcSSc)
1 trial -
CVHB937A12201
Novartis Pharmaceuticals
Alzheimer’s disease
1 trial -
CVHB937B12201
Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
CXXB750A12201
Novartis Pharmaceuticals
Heart Failure
1 trial -
CYTB323A12101
Novartis Pharmaceuticals
High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia
1 trial -
CYTB323G12101
Novartis Pharmaceuticals
Systemic Lupus Erythematosus., Lupus Nephritis
1 trial -
CYTB323J12201
Novartis Pharmaceuticals
Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)
1 trial -
CYTB323K12201
Novartis Pharmaceuticals
Diffuse cutaneous systemic sclerosis (dcSSc)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.